PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值

doi:10.6040/j.issn.1671-7554.0.2016.1285

摘要/Abstract

摘要： 目的探讨预后营养指数(PNI)及血红蛋白(HGB)评估中晚期非小细胞肺癌患者预后的临床价值。方法选取2013年8月至2015年8月首次确诊的、符合本研究条件的中晚期非小细胞肺癌患者的临床资料;通过电子病历系统、门诊及电话等方法对所有患者进行随访,随访截止到患者死亡或2016年8月;根据PNI中位数(46.52)及HGB中位数(115 g/L)将患者分为高PNI组、低PNI组及高HGB组、低HGB组;通过单因素及多因素分析PNI及HGB对患者总生存期(OS)的影响;制作两组患者的Kaplan-Meier生存曲线,同时行Log-rank检验。通过单因素分析PNI及HGB相关影响因素。结果单因素变量分析示首次确诊时年龄≥65岁、吸烟指数≥400、PNI<46.52、HGB<115 g/L的患者OS明显低于年龄<65岁、吸烟指数<400、PNI≥46.52、HGB≥115 g/L的患者OS(P<0.05);PNI与患者年龄、临床分期、胸腔积液及吸烟指数密切相关(P<0.05);HGB与患者年龄、体质量下降率密切相关(P<0.05)。多因素分析示仅PNI及HGB对患者OS的影响有统计学意义［Exp(B)=2.180, P<0.001;Exp(B)=2.032, P=0.001］。绘制Kaplan-Meier生存曲线同时行Log-rank检验示,高PNI组与低PNI组患者、高HGB组与低HGB组患者OS差异有统计学意义(P<0.001)。结论 PNI及HGB可作为中晚期非小细胞肺癌患者预后的独立危险因素。

关键词: 血红蛋白, 预后, 危险因素, 预后营养指数, 非小细胞肺癌

Abstract: Objective To explore the clinical value of prognosis of nutrition index(PNI)and hemoglobin(HGB)in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients. Methods A total of 120 cases of the middle to late stage non-small cell lung cancer patients were selected during August 2013 and August 2015. The clinical information and data of all patients were collected when they were first confirmed. All patients were followed-up by the date of death or August 2016 through electronic medical record system, outpatient and telephone, etc. The patients were divided into high and low PNI groups, and high and low HGB groups on the basis of the medians of PNI(46.52)and HGB(115 g/L). The impact of PNI and HGB on overall survival(OS)of patients was analyzed through single factor and multiple factors methods. The survival curves of two groups were produced by Kaplan-Meier method. The Log-rank test was exerted. The related influencing factors of PNI and HGB were analyzed through single factor method. Results The single factor analysis showed that the patients with age≥65 years, smoking index≥400, PNI<46.52, HGB<115 g/L when they were first confirmed had significantly lower OS than those with age<65 years, 山东大学学报 (医学版)55卷4期 -孙启晶,等.PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值 \=-smoking index<400, PNI≥46.52, HGB≥115 g/L(P<0.05). PNI were closely related to the age, clinical stages, pleural effusion and smoking index(P<0.05). HGB were closely related to the age and weight loss rate(P<0.05). The multiple factors analysis showed that only PNI and HGB were statistically significant on OS of the patients［Exp(B)=2.180, P<0.001; Exp(B)=2.032, P=0.001］. The survival curves and Log-rank test showed that low PNI and HGB groups had lower OS than high PNI and HGB groups(P<0.001). Conclusion PNI and HGB can be used as the independent risk factors for the middle to late stage non-small cell lung cancer patients.

Key words: Risk factors, Prognosis of nutrition index, Hemoglobin, Non-small cell lung cancer, Prognostic

中图分类号:

R734

孙启晶,陈方方,李春晓,张才擎. PNI及HGB评估中晚期非小细胞肺癌患者预后的临床价值[J]. 山东大学学报（医学版）, 2017, 55(4): 55-59.

SUN Qijing, CHEN Fangfang, LI Chunxiao, ZHANG Caiqing. Clinical value of PNI and HGB in evaluating the prognosis of the middle to late stage non-small cell lung cancer patients[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 55-59.

参考文献

[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
[2] Jones CD, Cummings IG, Shipolini AR, et al. Does surgery improveprognosis in patients with small-cell lung carcinoma?[J]. Interact Cardiovasc Thorac Surg, 2013, 16(3): 375-380.
[3] Tartari RF, Ulbrich-Kulczynski JM, Filho AF. Measurement of mid-arm muscle circumference and prognosis in stage Ⅳnon-small cell lung cancer patients[J]. Oncol Lett, 2013, 5(3): 1063-1067.
[4] Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients[J]. Nihon Geka Gakkai Zasshi, 1984, 85(9): 1001-1005.
[5] Yao ZH, Tian GY, Wan YY, et al. Prognostic nutritional index predicts outcomes of malignantpleural mesothelioma[J]. Cancer Res Clin Oncol, 2013, 139(12): 2117-2123.
[6] Wigren T, Oksanen H, Kellokumpu-Lehtinen P. A practical prognostic index for inoperable non-small-cell lung cancer[J]. Cancer Res Clin Oncol, 1997, 123(5): 259-266.
[7] Harrison LB, Chadha M, Hill RJ, et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes[J]. Oncologist, 2002, 7(6): 492-508.
[8] Migita K, Takayama T, Saeki K, et al. The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage[J]. Ann Surg Oncol, 2013, 20(8): 2647-2654.
[9] 钱桂生.肺癌不同病理类型发病率的变化情况及其原因[J].中华肺部疾病杂志(电子版), 2011, 4(1): 1-6. QIAN Guisheng. The incidence and reasons for the changes of different pathological types of lung cancer[J]. Clin J Lung Dis(Electronic Edition), 2011, 4(1): 1-6.
[10] de Marinis F, Rossi A, Di Maio M, et al. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology(AIOT)clinical practice guidelines[J]. Lung Cancer, 2011, 73(1): 1-10.
[11] Crinò L, Weder W, van Meerbeeck J, et al. ESMO Guidelines Working Group: early stage and locally advanced(non-metastatic)non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2010, 7(21): v103- v115.
[12] Jemal A, Bray F, Center MM, et al. Global cancerstatistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[13] Alexiou C, Onyeaka CV, Beggs D, et al. Do women live longer followinglung resection for carcinoma?[J]. Eur J Cardiothorac Surg, 2002, 21(2): 319-325.
[14] Coussens LM, Werb Z. Inflammation and cancer[J]. Nature, 2002, 420(6917): 860-867.
[15] Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203): 436-444.
[16] Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operative cancer[J]. Future Oncol, 2010, 6(1): 149-163.
[17] Proctor MJ, Morrison DS, Talwar D, et al. A Glasgow inflammation outcome study[J]. Eur J Cancer, 2011, 47(17): 2633-2641.
[18] Qiu C, Qu X, Shen H, et al. Evaluation of prognostic nutritional index in patients undergoing radical surgery with nonsmall cell lung cancer[J]. Nutr Cancer, 2015, 67(5): 741-747.
[19] Chamogeorgakis T, Anagnostopoulos C, Kostopanagiotou G, et al. Does anemia affect outcome after lobectomy or pneumonectomy in early stage lung cancer patients who have not received neo-adjuvant treatment?[J]. Thorac Cardiovasc Surg, 2008, 56(3): 148-153.
[20] Tomita M, Shimizu T, Hara M, et al. Impact of preoperative hemoglobin level on survival of non-small cell lungcancer patients[J]. Anticancer Res, 2008, 28(3): 1947-1950.
[21] MacRae R, Shyr Y, Johnson D, et al. Declining hemoglobinduring chemoradiotherapy for locally advanced non-small celllung cancer is significant[J]. Radiother Oncol, 2002, 64(1): 37-40.
[22] Hsu CL, Chen KY, Shih JY, et al. Advanced non-small cell lung cancer in patients aged 45 years or younger: outcome and prognostic factors[J]. BMC Cancer, 2012, 12: 241.
[23] Merlini L, Carteni G, Iacobelli S, et al. Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy[J]. Cancer Manag Res, 2013, 2(5): 205-214.
[24] 郝静,王秀问,蔡毅然,等.在非小细胞肺癌中急、慢性乏氧标记物HIF-1α、GLUT1表达的临床意义[J].山东大学学报(医学版),2005,43(8): 756-759. HAO Jing, WANG Xiuwen, CAI Yiran, et al. Expressions of HIF-1α and GLUT1 and their clinical significance in non-small cell lung cancer[J]. Journal of Shandong University(Healthy Sciences), 2005, 43(8): 756-759.
[25] Calabrich A, Katz A. Management of anemia in cancer patients[J]. Future Oncol, 2011, 7(4): 507-517.

相关文章 15

[1]	栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45-51.
[2]	史爽,李娟,米琦,王允山,杜鲁涛,王传新. 胃癌miRNAs预后风险评分模型的构建与应用[J]. 山东大学学报 (医学版), 2020, 1(7): 47-52.
[3]	路璐,孙志钢,张楠. 继发性嗜血细胞综合征1例[J]. 山东大学学报 (医学版), 2020, 1(7): 122-124.
[4]	李星凯,刘战业,姜运峰,李军. 原发性中央型和周围型肺鳞癌临床病理学及预后差异[J]. 山东大学学报（医学版）, 2017, 55(9): 73-78.
[5]	宗帅,肖东杰,刘华,郏雁飞,马晓丽,李焕杰,黎娉,郑燕,汪运山. CSN5在胃癌中的表达及与患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(7): 12-16.
[6]	董尧,宋亚林,田涛,高建国. 确诊8年未经治疗却无明显进展的阴茎恶性黑色素瘤1例报道[J]. 山东大学学报（医学版）, 2017, 55(3): 125-126.
[7]	林家香,郭子嘉,苏鹏,王晓,郭雅欣,吴晓娟,相磊,周志强, 王妍,崔秀杰,潘爱凤,郭成浩. 致癌蛋白CIP2A在乳腺导管上皮恶变中的作用及预测浸润性导管癌患者预后的能力[J]. 山东大学学报（医学版）, 2017, 55(3): 100-106.
[8]	戴建建,袁冰,张颖,林琦,袁苑,韩明勇. CT引导下¹²⁵I粒子植入治疗Ⅲ期非小细胞肺癌疗效与并发症的临床观察[J]. 山东大学学报（医学版）, 2017, 55(2): 32-37.
[9]	周兰兰,潘学谊,郭煜. 48例急性混合细胞表型白血病患者的临床特征及预后[J]. 山东大学学报（医学版）, 2017, 55(2): 79-83.
[10]	张希英,翟春颜,李劲松,韩博. 中国尤文肉瘤患者EZH2蛋白表达与临床病理学参数及预后的关系[J]. 山东大学学报（医学版）, 2017, 55(2): 84-91.
[11]	彭岳,冯振,谢厚耐,王晖,李猛,任万刚,刘通,彭忠民. 61例肺部多发病灶患者的外科治疗[J]. 山东大学学报（医学版）, 2017, 55(11): 42-46.
[12]	仇成轩, 杜怡峰. 重视阿尔茨海默病和老年痴呆症的人群干预研究[J]. 山东大学学报（医学版）, 2017, 55(10): 1-6.
[13]	王丽丽,霍彬,王磊,汪浩,侯定坤,霍小东,王金焕,臧立,曹强,柴树德,王海涛. 亚肺叶切除联合¹²⁵I粒子植入治疗早期肺癌有效性的Meta分析与系统评价[J]. 山东大学学报（医学版）, 2017, 55(10): 76-83.
[14]	杜蘅,袁晓东. 阿尔茨海默病病因及发病机制研究进展[J]. 山东大学学报（医学版）, 2017, 55(10): 21-27.
[15]	刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报（医学版）, 2017, 55(10): 84-89.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed